NEW YORK, NY / ACCESSWIRE / February 23, 2017 / Pawar Law Group announces a class action lawsuit on behalf of Endologix Inc. (or the “Company”) (ELGX) investors who purchased Endologix between August 2, 2016 and November 16, 2016 inclusive (the “Class Period”). The suit is for recovery of investor losses.

To participate in this class action lawsuit, visit the firm’s website at http://pawarlawgroup.com/cases/endologix/ or email Vik Pawar, Esq. at [email protected] or call toll free at (866) 999-0873.

No class has been certified in the above action yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Endologix did not have the requisite clinical data for FDA premarket approval of its Nellix® EndoVascular Aneurysm Sealing System; and (2) as a result, Endologix’s public statements were materially false and misleading at all relevant times. On November 16, 2016, Endologix announced that the FDA requested two-year follow-up data on patients enrolled in the EVAS-FORWARD-IDE study to assess Nellix. On this news, shares of Endologix fell $2.02 to close at $7.82 per share on November 16, 2016, damaging investors.

If you wish to serve as lead plaintiff, you must move the Court no later than March 6, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You may join the case here: http://pawarlawgroup.com/cases/endologix/ or email Vik Pawar, Esq. at [email protected]

Contact:

Vik Pawar, Esq.
Pawar Law Group
20 Vesey Street, Suite 1210
New York, NY 10007
Tel: (212) 571-0805
Fax: (212) 571-0938
[email protected]

For more information, please visit the source link below.